Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661895 · ClinicalTrials.gov registry record · Phase 4
Black Education and Treatment of Hypertension (BEAT HTN)
A Phase 4 study, sponsored by Creighton University.
- Completed
- Registry status
- Phase 4
- Development phase
- 99
- Enrollment target
NCT00661895: Completed Phase 4 study, sponsored by Creighton University.
NCT00661895 is a Phase 4 study that has completed, run by Creighton University. The registered enrollment target is 99 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00661895, a Phase 4 study, has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 99 participants
- Enrollment target
Study Summary
Clinical trials have yet to test the adequacy of HTN control in African Americans (AA) when both control and intervention groups are given free antihypertensive medications and are involved in usual versus intensive intervention strategies. Because of this, it has not yet been determined whether the method of prescribing antihypertensive medications according to JNC 7 guidelines is more, less, or equally as effective as prescribing antihypertensive medications and providing intensive behavioral and clinical interventions. Knowledge in this area of HTN treatment should better able medical and health practitioners to help their AA subjects control HTN. The BEAT Hypertension Clinic will evaluate this method of HTN control by proposing a program that will evaluate the difference in HTN control among subjects receiving usual care and free medications and subjects also receiving free medications, but additionally being treated in a clinic that operates in a more intensive manner in relationship to patient behavior modification, patient-clinician interactions, and physical and social environments. At the conclusion of the study, the BEAT Hypertension Clinic investigators will report findings and help to answer the question of whether medication alone or medication combined with intensive behavioral and clinical treatment is more effective in HTN control in the AA population.
Primary Outcome
Percentage of subjects who achieved JNC-VII defined blood pressure goals.
Interventions
- DRUG Lisinopril
- DRUG Hydrochlorothiazide
- DRUG Nifedipine XL
- DRUG Lisinopril and Hydrochlorothiazide
- DRUG Metoprolol tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
What the finished NCT00661895 record still lists
NCT00661895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 5 interventions - of which Lisinopril is the first listed.
NCT00661895 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00661895 about?
NCT00661895 is a clinical study titled "Black Education and Treatment of Hypertension (BEAT HTN)". Clinical trials have yet to test the adequacy of HTN control in African Americans (AA) when both control and intervention groups are given free antihypertensive medications and are involved in usual versus intensive intervention strategies. Because of this, it has not yet been determined whether the...
What is the current status of trial NCT00661895?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 99 participants. The study started on 2005-08. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00661895?
The interventions under investigation include: Lisinopril (DRUG), Hydrochlorothiazide (DRUG), Nifedipine XL (DRUG), Lisinopril and Hydrochlorothiazide (DRUG), Metoprolol tartrate (DRUG).
Who is sponsoring clinical trial NCT00661895?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00661895's enrollment target sits among peer trials
99 853rd of 2000 higher than 1,147 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia